III期ARTISTRY-2研究达主要终点,吉利德新型HIV二联疗法展现潜力

药事纵横
Dec 18

12月15日,吉利德宣布III期ARTISTRY-2研究取得积极顶线结果。该双盲试验评估了病毒学抑制的HIV成人患者从比克替拉韦50mg/恩曲他滨200mg/丙酚替诺福韦25mg片剂(BIKTARVY®,B/F/TAF)转换为比克替拉韦75mg/来那卡帕韦50mg固定剂量复方制剂(BIC/LEN)后的治疗反应。研究结果显示,BIC/LEN的疗效在统计学上非劣于BIKTARVY。吉利德计划将...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10